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Abstract 
 
Background. Left ventricular systolic dysfunction (LVSD) is a risk factor for atrial fibrillation (AF), 
but the atrial cellular electrophysiological mechanisms in humans are unclear. Objective. To 
investigate whether LVSD in patients who are in sinus rhythm (SR) is associated with atrial cellular 
electrophysiological changes which could predispose to AF. Methods. Right atrial myocytes were 
obtained from 214 consenting patients in SR who were undergoing cardiac surgery. Action potentials 
or ion currents were measured using the whole-cell-patch clamp technique. Results. The presence of 
moderate or severe LVSD was associated with a shortened atrial cellular effective refractory period, 
ERP (209±8 ms; 52 cells, 18 patients vs 233±7 ms; 134 cells, 49 patients; P<0.05); confirmed by 
multiple linear regression analysis. The LV ejection fraction (LVEF) was markedly lower in patients 
with moderate or severe LVSD (36±4%, n=15) than in those without LVSD (62±2%, n=31; P<0.05). 
In cells from patients with LVEF≤45%, the ERP and action potential duration at 90% repolarisation 
were shorter than in those from patients with LVEF>45%, by 24 and 18%, respectively. The LVEF 
and ERP were positively correlated (r=0.65, P<0.05). The L-type calcium ion current, inward rectifier 
potassium ion current, and sustained outward ion current was unaffected by LVSD. The transient 
outward potassium ion current was decreased by 34%, with a positive shift in its activation voltage, 
and no change in its decay kinetics. Conclusion. LVSD in patients in SR is independently associated 
with a shortening of the atrial cellular ERP, which may be expected to contribute to a predisposition to 
AF. 
 
Keywords 
Human; Left ventricular systolic dysfunction; Ejection fraction; Sinus rhythm; Atrial fibrillation; 
Electrophysiological remodelling; Isolated myocyte; Effective refractory period; Action potential 
duration; Ion current. 
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Introduction 
 Atrial fibrillation (AF) and congestive heart failure (CHF) frequently co-exist, and left ventricular 
systolic dysfunction (LVSD) may increase AF risk.
1
 The mechanisms of this predisposition to AF 
likely involve interacting adaptational changes, or remodelling, of atrial structure and electrical, 
mechanical, metabolic and neurohumoral activities. AF generation and maintenance may each involve 
atrial reentrant and non-reentrant electrical activity. Reentry is promoted by a shortening of the 
wavelength, due to a reduction in either the effective refractory period (ERP), conduction velocity, or 
both. Atrial cellular electrical remodelling in patients with persistent AF features a shortening of the 
ERP, which is considered to facilitate reentry in these patients.
2
 It is conceivable that, in patients who 
are in sinus rhythm (SR), a predisposition to AF in those with LVSD might involve an associated 
reduction in the atrial cellular ERP. However, the available data are scarce and conflicting, and often 
compounded by variability in patients’ disease states and drug treatments.
3
 In atrial cells isolated from 
patients with CHF, the action potential duration at 90% repolarisation (APD90), an important 
determinant of ERP, was either increased,
4
 unchanged
5,6
 or, when recorded at relatively high 
stimulation rate, shortened.
5
 A shortening,
6
 or no change,
4
 in atrial cell APD50 were also reported. 
However, the ERP has not been measured in atrial cells from patients with CHF or LVSD,
3
 and also 
remains to be correlated with the left ventricular ejection fraction (LVEF), an important index of 
LVSD and predictor of AF.
7
 Furthermore, the pattern of ionic remodelling in CHF or LVSD in human 
atrium also is presently unclear.
3
 For example, the L-type Ca
2+
 current (ICaL) was either decreased
8,9
 or 
unchanged,
5,10
 with either slowed
5
 or unchanged
8
 kinetics, and had either an increased
9
 or decreased
8,10
 
response to β-adrenergic stimulation. Studies of human atrial K
+
 currents have shown increased 
transient outward current (ITO), with no change in its voltage-dependence or decay, but with enhanced 
reactivation;
6
 a decreased inward rectifier (IK1);
4
 and an unchanged ultra-rapid delayed rectifier.
6
 
 The aims of this study, therefore, were two-fold. First, to investigate whether LVSD and reduced 
LVEF in patients who were in SR and undergoing cardiac surgery correlate with a shortening of atrial 
cellular ERP, which could contribute to a predisposition to AF. Second, to clarify the pattern of any 
accompanying ionic remodelling, by comparing various ion currents and their voltage- and time-
dependent characteristics between patients with and without LVSD.  
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Methods 
 Right atrial appendage tissue was obtained from 214 consenting patients who were in SR and 
undergoing cardiac surgery. Procedures were approved by the institutional research ethics committee. 
Atrial cells were isolated as described previously.
2
 Action potentials and ion currents were recorded 
using the whole-cell-patch clamp technique. Cells were superfused at 35-37
o
C with a physiological 
solution containing (mM): NaCl (130), KCl (4), CaCl2 (2), MgCl2 (1), glucose (10) and HEPES (10); 
pH 7.4, with Cd
2+
 (0.2 mM) added for some cells, to block ICaL when recording K
+
 currents. Either the 
perforated or conventional ruptured patch configuration was used. The proportion of cells in which the 
perforated patch was used (64%) was not different between the groups under comparison. The 
constituents of the pipette solutions used for the different types of recordings are as detailed 
previously.
11
 Action potentials were stimulated with 5 ms current pulses of 1.2x threshold, at 75 
beats/min (bpm) while injecting a small, constant current (set at the start of threshold measurement to 
clamp the maximum diastolic potential (MDP) to -80 mV, 1-2 min after attaining whole-cell).
2,11-13
 
The cellular ERP was then measured using a standard S1−S2 protocol. Ion currents were recorded by 
voltage-clamping. IK1 was stimulated with linear voltage ramps from -120−+50 mV at 24 mV/s, or 
with 500 ms pulses (0.2 Hz) increasing from -120−+50 mV in 10 mV steps, from a holding potential 
(HP) of -50 mV. ITO and the sustained outward current, ISUS, were stimulated with 100 ms pulses (0.33 
Hz), from -40−+60 mV, from a -50 mV HP. ISUS was measured as end-pulse current, and ITO as peak 
outward minus end-pulse current. ICaL was stimulated with 250 ms pulses (0.33 Hz), from -30−+60 
mV, from an HP of -40 mV. 
 Details of each patient’s clinical characteristics and drug treatments were obtained from the 
medical records, post-surgery. All patients were in SR on the day of surgery, confirmed from a pre-
surgery 12 lead ECG. An ECG was also available for the preceding day in 206 of 214 patients, and all 
confirmed SR. Patients were excluded if they had a documented episode of AF at any time pre-
surgery, if they were taking digoxin or a non-β1-selective β-blocker, or if their β1-blocker-treatment 
had started later than 7 days pre-surgery. Each patient was designated as having either “no LVSD”, 
“mild LVSD”, “moderate LVSD” or “severe LVSD”, from qualitative reports of assessments in the 
patient’s case record. The LVEF was obtained, in a subset of 58 patients, from either 
echocardiography (52%), radionuclide ventriculography (26%) or contrast ventriculography (22%).  
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Statistical methods 
Univariate measurements were compared between pairs of various subgroups of patients using 2-
sided, 2-sample unpaired Student's t-tests. Categorical data were compared using a χ
2
-test. All 
univariate electrophysiological data are expressed as cell means±1 standard error (SE), unless 
otherwise stated. Multiple linear regression analysis was used to further investigate relationships 
between the presence of LVSD and various electrophysiological measures, adjusted in a mixed effects 
linear model with the subject as a random effect, according to 10 covariates. Analyses were performed 
retrospectively, using “SAS PROC MIXED” in SAS 9.1.3 software (SAS Inst, USA). The group of 
patients with moderate or severe LVSD (19% of total) was used for statistical comparisons of cellular 
electrophysiology against patients with no LVSD whenever patient n permitted and unless otherwise 
stated, to maximise analysis sensitivity. All available information was incorporated. Therefore, the 
tables and statistical models are sometimes based on different numbers of subjects, reflecting some 
missing data for some covariates. P<0.05 was regarded as statistically significant. 
 
 
Results 
Patients’ characteristics 
The patients’ clinical characteristics and drug treatments are shown in Table 1. The majority (91%) 
suffered from angina and underwent CABG surgery. Valve surgery (AVR or MVR) was performed 
with or without CABG in 15% of patients. 36% of patients had mild, moderate or severe LVSD, and 
19% had moderate or severe LVSD. The majority of patients with LVSD had a history of MI and were 
taking an ACEI or ARB. 
[Insert Table 1] 
Changes in atrial cellular ERP and capacity associated with LVSD 
Atrial cells from patients with moderate or severe LVSD had a significantly shorter ERP than those 
from patients without LVSD (Figure 1A). The resting potential (Vm) before current-clamp was similar 
in patients with moderate or severe LVSD to no LVSD (-20±2 vs -17±1 mV, P>0.05). During current-
clamp, the holding current and MDP (taken during ERP-recording) also were similar between these 
groups (0.72±0.05 vs 0.68±0.03 pA/pF, and -82±1 vs -81±0 mV, respectively; P>0.05 for each). There 
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were no significant differences in other action potential measurements. In a sub-group of 37 patients 
for whom left atrial (LA) size was available, the LA was larger in patients with LVSD (4.4±0.2 cm, 
n=7) than in those without (3.8±0.1 cm, n=30; P<0.05). The ERP was similar in cells from patients 
with LA size≤ 4 cm (clinically recognised as normal
14
), at 245±22 ms, to those with LA>4 cm, at 
256±36 ms (P>0.05), and there was no significant correlation between LA size and ERP (P>0.05). 
The right atrial (RA) size was not available, though RA cell capacity was increased in LVSD (Figure 
1C). The incidence of chronic β1-blocker use (which is associated with ERP-prolongation
11,12
) in 
patients from whom ERP was recorded, was 67% in those with moderate or severe LVSD vs 59% in 
those without LVSD (P>0.05). ERP-shortening associated with LVSD was maintained when patients 
were sub-analysed by chronic β1-blockade. In non-β-blocked patients, ERP was 179±13 ms in 27 cells 
from 8 patients with mild, moderate or severe LVSD vs 212±9 ms in 47 cells from 20 patients with no 
LVSD (P<0.05). Furthermore, in patients who underwent CABG-only (excludes all AVR, MVR, 
ASDR & VSDR), the magnitude of change in ERP and capacity associated with moderate or severe 
LVSD was largely maintained: ERP=213±10 vs 241±8 ms, P>0.05 (0.053); capacity=85±2 vs 77±1 
pF, P<0.05). Finally, ERP-shortening associated with LVSD was confirmed by multiple linear 
regression analysis, adjusting for 10 covariates considered to be of particular importance (Table 2). 
[Insert Figure 1] 
[Insert Table 2] 
Correlation between LVEF and atrial cellular electrophysiology 
Within the sub-group of 58 patients whose LVEF was available, the qualitative assessment of 
increasing severity of LVSD was associated with a progressive and significant reduction in LVEF, 
compared with that recorded in patients without LVSD (Figure 2A). In patients with LVEF≤ 45% (a 
clinically accepted threshold for LVSD
14
), the APD90, but not APD75 or APD50, was significantly 
shorter than in patients with LVEF>45%, by 18% (Figure 2B), and the ERP was significantly shorter, 
by 24% (Figure 2C). Furthermore, the action potential maximum upstroke velocity (dV/dtmax) was 
significantly greater in patients with LVEF≤ 45%, by 11%, than in patients with LVEF>45% (Figure 
2D). The holding current was similar between these groups (0.67±0.06 vs 0.60±0.04 pA/pF, P>0.05), 
and there were no significant differences in other action potential measurements. There was a 
significant correlation (Spearman rank correlation test) between patients’ atrial cellular ERP and 
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LVEF, with ERP shortening with decreasing LVEF (Figure 2E). However, there was no significant 
correlation between dV/dtmax and LVEF with this test (P>0.05). There was also no correlation 
between LVEF and holding current (P>0.05), nor between ERP and dV/dtmax (P>0.05, n=49 cells). 
[Insert Figure 2] 
Changes in atrial K
+
 currents associated with LVSD 
Atrial cells from patients with LVSD had a significantly lower peak ITO density (at +60 mV) than 
patients without LVSD, by 34% (Figure 3A&B). This reduction was maintained when patients were 
sub-analysed by chronic β1-blockade (itself associated with ITO-decrease
12
). In β1-blocked patients, ITO 
was 7.4±1.0 pA/pF in 15 cells from 9 patients with LVSD of any designation vs 10.0±0.6 pA/pF in 38 
cells from 23 patients with no LVSD (P<0.05). LVSD was associated with significant ITO-reduction at 
all voltages between +20 and +60 mV (Figure 3C). Furthermore, the voltage of half-maximal 
activation (Vact50), assessed from Boltzmann relations, was significantly more positive, by 5 mV, in 
patients with LVSD (Figure 3D). The-time course of ITO inactivation was bi-exponential. There was no 
significant difference in the time constant (τ) or amplitude (A) of either phase of inactivation, 
measured at +60 mV, between patients with and without LVSD (Figure 3E). Peak ISUS was similar in 
cells from patients with LVSD (9.1±1.3 pA/pF; n=15 cells, 8 patients) to those without (10.3±0.6 
pA/pF; n=72 cells, 31 patients, P>0.05). Peak IK1 was not significantly different between patients with 
and without LVSD (Figure 3F&G). This pattern of K
+
 current changes was maintained in the sub-
group of CABG-only patients: ITO=8.3±1.2 vs 12.7±0.7 pA/pF, P<0.05; Vact50=30±4 vs 25±1 mV, 
P<0.05; with ISUS and IK1 again unaltered (P>0.05). 
[Insert Figure 3] 
Atrial ICaL characteristics associated with LVSD 
Peak ICaL density (at +10 mV) was similar in cells from patients with and without LVSD (Figure 
4A&B). This similarity was maintained in the CABG-only sub-group: -6.0±0.5 vs -5.4±0.3 pA/pF, 
P>0.05. ICaL also was not significantly different between patients with LVEF≤ 45% (-4.7±0.5 pA/pF; 
n=51 cells, 13 patients) and >45% (-5.7±0.5 pA/pF; n=54 cells, 15 patients, P>0.05). ICaL was not 
different at any voltage, between patients with and without LVSD (Figure 4C), and Vact50 also was 
similar (Figure 4D). ICaL decay was bi-exponential, and both time constants and amplitudes of decay, 
measured at +10 mV, were similar between patients with and without LVSD (Figure 4E). In a sub-
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group of cells, the magnitude of increase in peak ICaL in response to acute superfusion with either 
isoproterenol or 5-hydroxytryptamine at near-maximally effective concentrations
13,15
 was assessed. 
There was no significant difference between cells from patients with and without LVSD in the 
response to either drug (Figure 4F&G). 
[Insert Figure 4] 
 
 
Discussion 
 Left ventricular systolic dysfunction in patients who were in SR was independently associated 
with shortening of their atrial isolated cellular ERP. Previous reports of associations between atrial cell 
APD, an important determinant of ERP, and human CHF or LVSD are equivocal, likely due to 
differing experimental conditions and/or clinical characteristics of patients studied.
3,4,6
 For example, 
APD90 was longer in cells from explanted, than from donor, hearts,
4
 but not different
6
 or shortened
5
 
between LVEF<45% and >60%, despite action potential plateau depression.
4,6
 A comparison of the 
present data with those studies is difficult, however, since they included cells with resting potentials of 
-50 mV or more positive
4,6
 which would have relatively slow responses, or patients with chronic AF.
4
 
Furthermore, whilst AF accompanies a number of pathologies, the present cohort was dominated by 
coronary artery disease. In a single clinical study, CHF was associated with a moderate (≤ 10%) atrial 
ERP-lengthening at rates ≥ 100 bpm, but lower, physiological, rates were not studied.
16
 The relevance 
of the measurement of the ERP and APD90 in isolated cells is supported by the demonstration that 
human chronic AF was associated with shortening of either, or both parameters in atrial isolated 
cells,
2,15,17
 as in atrial isolated tissues,
17,18
 and RA appendages in-vivo.
19
 The present ERP-shortening 
associated with LVSD may be expected, therefore, to contribute to a shortened atrial ERP in-vivo, and 
consequently, a shortened reentrant wavelength. On the other hand, LVSD was associated with an 
increase in dV/dtmax, which might oppose wavelength-shortening, by increasing conduction velocity. 
However, the dV/dtmax increase was smaller (11%) than the ERP decrease (24%) and, moreover, 
should increase conduction velocity by only 4%, according to a mathematical model of a cardiac 
fibre.
20
 The combined observed ERP and dV/dtmax changes should, therefore, shorten the wavelength 
by ~20%. 
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 The consequence of such wavelength-shortening, in the atria of patients in SR with LVSD, would 
be an increased propensity to reentry. Consistent with that, atrial wavelength-shortening that was 
produced either by drugs
21
 or chronic AF,
22
 increased the vulnerability to induction of AF. 
Furthermore, CHF or LVSD may cause additional atrial electrophysiological changes that may 
predispose to AF, particularly in the presence of a shortened wavelength. CHF promoted 
afterdepolarisations in canine atrial cells,
23,24
 possibly from [Ca
2+
]i-overload
24
 and enhanced Na
+
/Ca
2+
 
exchanger current,
25
 which might produce triggered activity in-vivo and facilitate the initiation of 
reentry. Elevated sympathetic tone, which may accompany CHF, could promote such activity. 
However, the present experiments with isoproterenol suggest that this would not involve an altered 
ICaL response to β-stimulation. CHF also causes fibroblasts and collagen to accumulate between fibres 
or cells of both atria,
26
 associated with disturbed local conduction, perhaps facilitating microreentry.
26
 
Any associated cellular uncoupling may be expected to have a greater influence on conduction 
velocity than the present change in dV/dtmax,
20
 which would result in a correspondingly greater 
reduction in wavelength and predisposition to AF. Furthermore, atrial fibrosis and susceptibility to AF 
may persist in CHF after the reversal of ionic remodelling.
27
 
 The ionic changes we found in LVSD and which might, therefore, have contributed to the atrial 
ERP-shortening, were a reduction in ITO, in line with the shift in its activation voltage. Previous reports 
of changes in human atrial ITO associated with cardiac disease include a reduction with atrial dilation
28
 
and an increase with LVSD.
6
 However, the latter may have been compounded by the lower proportion 
of patients treated with β-blockers in the LVSD group,
6
 since such treatment is associated with 
decreased ITO in human atrium.
12
 A decreased atrial ITO is also a consistent feature of the canine model 
of CHF.
25,29
 However, it is unknown what effect a reduction in ITO might have on the human atrial 
action potential, due to a lack of availability of specific ITO blockers. Mathematical modelling 
suggested either a shortening or lengthening of APD90, depending on which of two human atrial 
models (which had differing baseline ITO) was studied.
30
 Furthermore, either shortening or lengthening 
of atrial APD90 occurred in a canine model, depending on the initial level of ITO.
31
 In that model, in 
support of a link between the present reduction in ITO and APD90, a complex coupling of ITO with ICaL 
was reported such that ITO reduction shortened APD90 by reducing the driving force and amplitude of 
ICaL, secondary to phase 1 suppression.
31
 The absence of change in IK1 was consistent with studies of 
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CHF in dogs,
25,29
 although a decrease was reported in 3 patients with CHF.
4
 Furthermore, the absence 
of change in ISUS was consistent with both a human
6
 and canine
25
 study. The lack of change in ICaL was 
consistent with two reports of human LVSD,
5,10
 although a decrease was also reported, in two 
others.
8,9
 In the more recent study,
9
 ICaL decrease was independently associated with both decreased 
LV function and mitral valve disease. However, a comparison with the present data is difficult due to 
differing overall clinical characteristics of the patients between the two studies (e.g., a higher 
incidence of valvular disease in the Dinanian study
9
), and is also potentially compounded by the 
differing recording temperatures and [Ca
2+
]i-buffering conditions used. The unaltered ICaL voltage-
dependence and decay were in line with the majority of reports.
5,8
 The action potential dV/dtmax 
depends predominantly on Na
+
 conductance, determined by Na
+
 current (INa) availability, in turn 
dependent on Na
+ 
channel characteristics and diastolic voltage.
20
 INa was not measured here, so the 
mechanism of dV/dtmax increase associated with LVSD is unknown. However, any contributory 
changes in INa availability potentially arising from altered density or time- or voltage-dependence of 
activation or inactivation would have been independent of diastolic voltage, since this was ~-80 mV in 
all cells. Increased dV/dtmax could arise from the ITO reduction, since it has been suggested
32
 that this 
current’s rapid activation may oppose INa during phase 0. 
 The resolution of the ionic mechanisms of the action potential and ERP changes will require 
measurement of additional currents, as well as [Ca
2+
]i-handling characteristics,
3
 in future studies. 
Nevertheless, we demonstrate here that the overall pattern of atrial ionic remodelling associated with 
LVSD is clearly different from that already associated with human chronic AF,
3
 in which both ICaL and 
ITO were markedly decreased, and IK1 was increased. In line, a disparate pattern of atrial ionic 
remodelling was also demonstrated in dogs between chronic ventricular tachypacing (VTP)-induced 
CHF and chronic atrial tachypacing.
29
 Furthermore, the present work highlights species- and/or 
ventricular pathology-dependent differences in atrial ionic remodelling, and the importance of 
obtaining clinical data. In particular, ICaL was clearly unchanged in the present study, yet moderately 
decreased in canine VTP-induced CHF.
25,29
 The slow delayed rectifier (IKS) also was decreased in 
canine CHF,
25,29
 perhaps contributing to an increase in APD or ERP in some studies of that 
model
23,24,29
 (though ERP was unchanged in others
26,33
), yet the contribution of IKS to human atrial 
ERP may be negligible. 
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Limitations of the study 
1: The enzymatic isolation of myocytes from atrial appendage tissue is recognised to depolarise Vm. 
We current-clamped Vm to overcome this and prevent INa inactivation. However, whilst un-clamped 
Vm was similar in patients with and without LVSD, Vm in-vivo may vary with pathology, with the 
potential to affect ERP in clamped cells. 2: LV function was assessed qualitatively or quantitatively, 
rather than uniformly for all patients. 3: The possibility of asymptomatic AF having been missed 
cannot be excluded. 
Clinical implications 
The clinical implications of the present data are that the treatment of patients who have LVSD and are 
in SR, with drugs that prolong ERP, might be expected to attenuate an atrial cellular 
electrophysiological predisposition to AF. In support, amiodarone and dofetilide, the only anti-
arrhythmic agents currently recommended for maintenance of SR in patients with AF and CHF,
1
 each 
prolong ERP, including in electrically-remodelled atria.
34,35
 Furthermore, amiodarone reduces the 
occurrence of new-onset AF in CHF.
1
 Renin-angiotensin-aldosterone system (RAAS) inhibitors also 
reduce new-onset AF in CHF, as may β-blockers.
1
 RAAS inhibitors may inhibit conduction 
abnormalities caused by structural remodelling, rather than altering ERP,
33
 but the effect of β-blockers 
may involve atrial ERP-prolongation, as demonstrated in atrial cells from patients in SR.
11,12
 
Furthermore, in patients with LVSD post-MI, the non-selective β-blocker carvedilol exerted a 
powerful atrial anti-arrhythmic effect, even in patients already taking an ACEI.
36
 
Conclusion 
The present work contributes to the understanding of the pattern of atrial cellular electrophysiological 
changes associated with, and potentially caused by, LVSD in patients who underwent cardiac surgery. 
The cellular ERP-shortening, which might contribute to a predisposition to AF, may represent a 
potential therapeutic target for maintaining SR in patients with LVSD. 
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Table 1. Patients’ characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are numbers of patients (n, and % of total) with selected clinical characteristics, except for age 
and heart rate (means±SE), in groups of patients with and without LVSD. “Any”=mild, moderate or 
severe. ACEI=angiotensin converting enzyme inhibitor. ARB=angiotensin receptor blocker. 
CCB=calcium channel blocker. MI=myocardial infarction. HT=hypertension. CABG=coronary artery 
bypass graft surgery. AVR=aortic valve replacement. MVR=mitral valve replacement. ASDR=atrial 
septal defect repair. VSDR=ventricular septal defect repair. *=P<0.05 vs LVSD none. 
 
 LVSD 
none 
LVSD 
any 
LVSD 
mod/sev 
 n % n % n % 
Patient details       
 Total 138 - 76 - 40 - 
 Male 97 70 62 82 33 83 
 Age (years) 63±1 - 62±1 - 63±2 - 
 Heart rate (bpm) 63±1 - 64±2 - 64±2 - 
Drug       
 Beta1-blocker 90 65 52 68 28 70 
 ACEI or ARB 63 46 51 67* 29 73* 
 CCB 58 42 27 36 14 35 
 Statin 111 80 66 87 33 83 
Disease       
 Angina 124 90 70 92 36 90 
 History of MI 38 28 51 67* 31 78* 
 History of HT 81 59 38 50 18 45 
 Diabetes 14 10 13 17 7 18 
Operation       
 CABG only 114 83 66 87 34 85 
 AVR only 11 8 5 7 4 10 
 CABG + AVR 8 6 4 5 2 5 
 MVR only 1 1 1 1 0 0 
 CABG + MVR 2 1 0 0 0 0 
 ASDR only 1 1 0 0 0 0 
 VSDR only 1 1 0 0 0 0 
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Table 2. Multiple linear regression analysis of atrial cellular electrophysiology 
 
 
 
 
 
 
 
 
Estimated changes in electrophysiological (EP) variables associated with LVSD, adjusting for the 
covariates: age, sex, β-blocker-treatment, ACEI/ARB-treatment, CCB-treatment, history of MI, 
history of HT, valve replacement surgery, diabetes, and heart rate. 
Patient n EP 
variable LVSD 
none 
LVSD 
mod 
/sev 
Estimated 
change in EP 
with LVSD 
mod/sev 
95% 
confidence 
interval 
P 
ERP 49 18 -26 ms -49−-3 0.027 
APD90 54 21 -20 ms -49−+9 0.17 
APD50 54 21 +4 ms -5−+13 0.36 
dV/dtmax 54 21 +4 V/s -20−+28 0.76 
ITO 40 6 -3.2 pA/pF -7.5−+1.0 0.14 
ITO Vact50 39 5 +5 mV -2−+13 0.15 
ICaL 73 19 -0.1 pA/pF -1.6−+1.5 0.92 
IK1 40 10 +0.4 pA/pF -0.9−+1.7 0.57 
Capacity 135 38 +6 pF -1−+13 0.074 
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Figure legends 
 
Figure 1 
Change in ERP and capacity of atrial cells from patients with LVSD. A. Representative, 
superimposed action potentials stimulated by the 7
th
 and 8
th
 of a train of current pulses, S1, followed by 
responses to a premature, S2, in a cell from a patient with no LVSD (upper trace) and moderate/severe 
LVSD (lower). ERP (bar)=longest S1−S2 which failed (
 
) to produce an S2 response of 
amplitude>80% of S1. Mean±SE ERP (B) and capacity (C) of cells from patients with no LVSD (
 
; 
n=134 cells, 49 patients for ERP, and 535 cells, 135 patients for capacity) and moderate/severe LVSD 
(
 
; n=52 cells, 18 patients for ERP, and 152 cells, 38 patients for capacity). *=P<0.05 vs 
 
. 
 
Figure 2 
Associations and correlations between LVEF, LVSD and atrial cellular electrophysiology. A. 
Mean±SE LVEF in patients with no LVSD (
 
; n=31) vs mild (n=12), moderate (n=11) and severe 
(n=4) LVSD (
 
). Comparison of APD at 50, 75 and 90% repolarisation (B), ERP (C) and dV/dtmax 
(D) between patients with LVEF>45% (horizontal stripes; n=27-38 cells, 10-13 patients) and ≤45% 
(diagonal stripes; n=22-26 cells, 7-8 patients). *=P<0.05; NS=not significant, vs LVEF>45%. E. 
Correlation between LVEF and ERP. Points are means of cell data from individual patients (n=49 
cells, 17 patients).  
 
Figure 3 
Changes in atrial K
+
 currents associated with LVSD. ITO recordings (A), peak density (B), current-
voltage relationships (C), Vact50 (D) and decay kinetics (E) in no LVSD (
 
; n=72-81 cells, 38-40 
patients) and moderate/severe LVSD (
 
; n=11-12 cells, 5-6 patients). IK1 recordings (F) and density 
at -120 mV (G) in no LVSD (
 
; n=99 cells, 40 patients) and moderate/severe LVSD (
 
; n=20 cells, 
10 patients).  
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Figure 4 
ICaL characteristics in atrial cells from patients with and without LVSD. ICaL recordings (A), peak 
density (B), current-voltage relations (C), Vact50 (D) and decay kinetics (E) in no LVSD (
 
; n=167-
222 cells, 61-73 patients) and moderate/severe LVSD (
 
; n=36-65 cells, 12-19 patients). Comparison 
of stimulatory effects on ICaL of isoproterenol (ISO; 50 nM) (F) and 5-hydroxytryptamine (5-HT; 10 
µM) (G) between no LVSD (
 
; n=45 cells, 19 patients for ISO; 37 cells, 23 patients for 5-HT) and 
moderate/severe LVSD (
 
; n=12 cells, 6 patients for ISO; 10 cells, 5 patients for 5-HT). 
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